Addendum to NICE guideline 100, alcohol-use disorders diagnosis and management of physical complications

A decision was made to update the NICE guideline on management of alcohol use disorders (CG100) following an exceptional surveillance review of corticosteroid treatment for alcohol-related diseases. Topic experts felt that recent publication of the NIHR-funded STOPAH trial represented significant ne...

Full description

Bibliographic Details
Corporate Author: National Institute for Health and Care Excellence (Great Britain)
Format: eBook
Language:English
Published: London National Institute for Health and Care Excellence (UK) 2017, April 2017
Series:NICE guideline addendum: methods, evidence, and recommendations
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 01637nam a2200289 u 4500
001 EB001897184
003 EBX01000000000000001060189
005 00000000000000.0
007 tu|||||||||||||||||||||
008 200523 r ||| eng
245 0 0 |a Addendum to NICE guideline 100, alcohol-use disorders  |h Elektronische Ressource  |b diagnosis and management of physical complications  |c developed by the National Institute for Health and Care Excellence 
246 3 1 |a Alcohol-use disorders 
260 |a London  |b National Institute for Health and Care Excellence (UK)  |c 2017, April 2017 
300 |a 1 PDF file (128 pages)  |b illustrations 
505 0 |a Includes bibliographical references 
653 |a Alcohol-Related Disorders / complications 
653 |a United Kingdom 
653 |a Alcohol-Related Disorders / therapy 
653 |a Alcohol-Related Disorders / diagnosis 
710 2 |a National Institute for Health and Care Excellence (Great Britain) 
740 0 2 |a Alcohol use disorders 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a NICE guideline addendum: methods, evidence, and recommendations 
856 4 0 |u http://www.ncbi.nlm.nih.gov/books/NBK550001  |3 Volltext 
082 0 |a 610 
520 |a A decision was made to update the NICE guideline on management of alcohol use disorders (CG100) following an exceptional surveillance review of corticosteroid treatment for alcohol-related diseases. Topic experts felt that recent publication of the NIHR-funded STOPAH trial represented significant new evidence that could have an impact on current guideline recommendations